CLINICAL AND PATHOLOGOANATOMIC CHARACTERISTICS OF ADVERSE OUTCOMES OF SARS-COV-2 IN A LEVEL III HOSPITAL
Main Article Content
Abstract
Aim. Clinical and pathological analysis of adverse outcomes of SARS-CoV-2 in a repurposed level III infectious diseases hospital.
Materials and methods: The analysis of case histories and the results of postmortem examination of deceased SARS-CoV-2 patients hospitalized in a re-profiled infectious diseases hospital, created on the basis of a level III hospital, in the period 06.12.2020 to 11.12.2020 was carried out. Statistical analysis was carried out using the Statsoft Statistica 6.0 software. Absolute values were described by the median (Me) and interquartile range, relative values – by percentage.
Results. The mortality rate for SARS-CoV-2 in a repurposed infectious diseases hospital over a five-month period was 11.9 %. Pathological examination of the deaths from SARS-CoV-2 revealed pneumonia in 82.4 % (72.1 % bilateral), hydrothorax in 47.4 %, pulmonary edema in 94.8 %, myocardial infarction in 88.6 %, PE in 5.1 %, sepsis in 32.9 %. The causes of death of patients with COVID-19 were: pulmonary heart failure – 65.9 %, multiple organ failure – 29.8 %, edema and dislocation of the brain – 17.5 %, PE – 5.1 %.
Conclusion. Mortality in a re-profiled infectious diseases hospital on the basis of a level III hospital was comparable in value to other similar institutions. In patients who died from COVID-19, the following adverse factors prevailed: old age, female sex, polymorbid pathology.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Online statistics of coronavirus infection. Russian (Онлайн статистика коронавирусной инфекции.) Available from: https://www.worldometers.info/coronavirus (дата обращения 10.12.20)
Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92(6): 577-583. doi: 10.1002/jmv.25757
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian Ch, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; e3319. doi: 10.1002/dmrr.3319
Kang SJ, Jung SI. Age-Related Morbidity and Lethality among Patients with COVID-19. Infect Chemother. 2020; 52(2): 154-164. doi: 10.3947/ic.2020.52.2.154
WHO reference number: WHO/2019-CoV/Sci_Brief/Lethality/2020.1
Interim guidelines «Prevention, diagnosis and treatment of new coronavirus infection (Сovid-19)». Ministry of Health, 2020. Russian (Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (Сovid-19)». Минздрав, 2020)
Corcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020; 14(2): 125-128. doi: 10.3855/jidc.12600
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323(20): 2052-2059. doi: 10.1001/jama.2020.6775
Gharebaghi N, Farshid S, Boroofeh B, et al. Evaluation of Epidemiology, Clinical Display, Prognosis, Diagnosis and Treatment in Patients with COVID-19. Int J Clin Pract. 2021; e14108. doi: 10.1111/ijcp.14108
Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020. doi:10.1001/jama.2020.4326
Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 lethality risk for older men and women. BMC Public Health. 2020; 20(1): 1742. doi: 10.1186/s12889-020-09826-8
Boccia S, Ricciardi W, Ioannidis JPA. What Other Countries Can Learn From Italy During the COVID-19 Pandemic. JAMA Intern Med. 2020; 180(7): 927-928. doi: 10.1001/jamainternmed.2020.1447
Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020; 1-8. doi: 10.1007/s42399-020-00363-4
Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract. 2020; 14(4): 295-300. doi: 10.1016/j.orcp.2020.07.002
Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020; 92(10): 1915-1921. doi: 10.1002/jmv.25889